A London clinic has become the first in Europe to roll out two Alzheimer’s wonder drugs privately after they were rejected ...

One described the approval of lecanemab as “no panacea” for patients, for example, while another went as far as to suggest that, in their eyes, donanemab offered “no net benefit” at all.

Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years. Research on ...

Donanemab and Lecanemab for Early Alzheimer’s: What You Need to Know Donanemab (Kisunla) and lecanemab (Leqembi) slow early-stage Alzheimer’s progression by targeting beta-amyloid ...

Mike, who is from Kent, said: "I feel more confident every day." Donanemab, made by Eli Lilly, works in the same way as lecanemab - developed by companies Eisai and Biogen - which created ...

Eli Lilly has been unable to secure an accelerated FDA approval for its anti-amyloid Alzheimer's disease therapy donanemab based ... Eisai and Biogen's Leqembi (lecanemab) onto the US market ...

Drugs, including antibiotics, antivirals, vaccinations, and anti-inflammatory medications, are linked to a lower risk of ...

Donanemab works by removing a sticky protein ... We observed a similar narrative unfold this past summer when Leqembi (lecanemab) was approved by the British regulatory authority in August ...

Not only has medical journal The Lancet added two new risk factors for the condition (high LDL cholesterol and vision loss), but dementia-slowing drugs donanemab and lecanemab were approved for ...

said disease-modifying therapies like Donanemab and Lecanemab "offer a new horizon of hope in the fight against dementia". She said that while they respect NICE's decision not to fund the drug ...